Drug Trial Radar · NCT04704219
Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
160
Actual
Start
Feb 23, 2021
Primary completion
Jan 27, 2025
Study completion Oct 21, 2025
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- Eisai Inc.
- First posted
- Jan 11, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 120 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being performed as a single-arm open-label study in order to rapidly provide information on the potential benefits of the combination of pembrolizumab and lenvatinib in participants with previously untreated advanced/metastatic non-clear cell renal cell carcinoma.
Conditions
- Renal Cell Carcinoma
Interventions
PembrolizumabBiological
Pembrolizumab 400 mg, every 6 weeks (Q6W) intravenous (IV) up to 18 infusions or up to progressive disease or discontinuation.
LenvatinibDrug
Lenvatinib 20 mg, daily (QD), oral, until progressive disease or discontinuation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: Up to approximately 47 months
Locations
56 sites in 14 countries. Site status is shown where the registry gives one.
Georgetown University Medical Center ( Site 0001)
Washington D.C., District of Columbia
St. Vincent Frontier Cancer Center ( Site 0004)
Billings, Montana
Comprehensive Cancer Centers of Nevada ( Site 0010)
Las Vegas, Nevada
Memorial Sloan Kettering Cancer Center ( Site 0015)
New York, New York
Fox Chase Cancer Center ( Site 0011)
Philadelphia, Pennsylvania
Vanderbilt University Medical Center ( Site 0008)
Nashville, Tennessee
Seattle Cancer Care Alliance ( Site 0014)
Seattle, Washington
MEDICAL COLLEGE OF WISCONSIN ( Site 0006)
Milwaukee, Wisconsin
Macquarie University-MQ Health Clinical Trials Unit ( Site 0405)
Macquarie Park, New South Wales, Australia
Calvary Mater Newcastle ( Site 0403)
Waratah, New South Wales, Australia
Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Si
Brisbane, Queensland, Australia
Ashford Cancer Centre Research ( Site 0404)
Kurralta Park, South Australia, Australia
Monash Health ( Site 0400)
Clayton, Victoria, Australia
Fiona Stanley Hospital ( Site 0402)
Murdoch, Western Australia, Australia
BC Cancer Vancouver-Clinical Trials Unit ( Site 1500)
Vancouver, British Columbia, Canada
Sunnybrook Health Sciences Centre ( Site 1501)
Toronto, Ontario, Canada
Princess Margaret Cancer Centre ( Site 1504)
Toronto, Ontario, Canada
CHU de Quebec - Université Laval - Hotel Dieu de Quebec ( Site 1502)
Québec, Quebec, Canada
Institut de cancérologie Strasbourg Europe (ICANS) ( Site 1007)
Strasbourg, Alsace, France
Centre François Baclesse ( Site 1000)
Caen, Calvados, France
Centre de Cancérologie du Grand Montpellier ( Site 1005)
Montpellier, Languedoc-Roussillon, France
centre hospitalier lyon sud ( Site 1003)
Pierre-Bénite, Rhone, France
Gustave Roussy ( Site 1002)
Villejuif, Val-de-Marne, France
Debreceni Egyetem Klinikai Kozpont-Onkológiai Klinika ( Site 0300)
Debrecen, Hungary
Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Okta-Klinikai Onkológiai és Sugárterápiás C
Miskolc, Borsod-Abauj Zemplen county, Hungary
Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház-Onkologiai Kozpont ( Site 0303)
Szolnok, Jász-Nagykun-Szolnok, Hungary
Országos Onkológiai Intézet-Urogenital Tumors Department and Clinical Pharmacology ( Site 0304)
Budapest, Pest County, Hungary
Tallaght University Hospital ( Site 1600)
Dublin, Ireland
Azienda Ospedaliera Santa Maria Terni-SC Oncologia ( Site 0900)
Terni, Italy
Fondazione Policlinico Universitario Agostino Gemelli-Medical Oncology ( Site 0901)
Rome, Lazio, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 0903)
Milan, Lombardy, Italy
Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Roma-Oncology Unit ( Site 0902)
Verona, Veneto, Italy
Szpital Kliniczny im. Przemienienia Panskiego Uniwersytetu M-chemotherapy department ( Site 0800)
Poznan, Greater Poland Voivodeship, Poland
Luxmed Onkologia sp. z o. o. ( Site 0802)
Warsaw, Masovian Voivodeship, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (
Warsaw, Masovian Voivodeship, Poland
SHBI Leningrad Regional Clinical Oncology Dispensary-Clinical Trials Department ( Site 0607)
Saint Petersburg, Russia
Russian Scientific Center of Radiology-Russian Scientific Center of Radiology ( Site 0602)
Moscow, Moscow, Russia
Volga District Medical Center-Urology Department ( Site 0604)
Nizhny Novgorod, Nizhny Novgorod Oblast, Russia
Nizhegorodsky Regional Oncology Dispensary, Branch #2-chemotherapy ( Site 0605)
Nizhny Novgorod, Nizhny Novgorod Oblast, Russia
Severance Hospital, Yonsei University Health System-Medical oncology ( Site 1302)
Seoul, South Korea
Showing 40 of 56 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.